³í¹®) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial ¿¬¼¼¾Ïº´¿ø À§¾Ï¼¾ÅÍ Á¾¾ç³»°ú ¶ó¼±¿µ ±³¼ö(»çÁø)ÆÀ